{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:50:32Z","timestamp":1777477832395,"version":"3.51.4"},"reference-count":21,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,4,16]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To capture variations in tofacitinib treatment response in psoriatic arthritis (PsA) by identifying patient groups with distinct disease activity trajectories.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were pooled post hoc from two phase 3 studies (OPAL Broaden, OPAL Beyond) in patients with PsA receiving tofacitinib 5 or 10\u2009mg twice daily (n=225, n=226, respectively). Psoriatic Arthritis Disease Activity Score (PASDAS) to month 6 was used in group-based trajectory modelling to identify distinct treatment response groups based on disease state (very low\/low\/moderate\/high disease activity (VLDA\/LDA\/MoDA\/HDA, respectively)). Baseline characteristics, PASDAS components to month 6 and adverse events (AEs) were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Five trajectory groups were identified for both tofacitinib doses: groups improved from MoDA\u2192VLDA\/LDA (group 1); HDA\u2192VLDA (group 2); HDA\u2192MoDA rapidly (group 3) or gradually (group 4) or remained in HDA (group 5). Groups 4\/5 generally had significantly higher baseline PsA clinical domain scores than groups 1\u20123, except for Psoriasis Area and Severity Index\/Nail Psoriasis Severity Index. Baseline Leeds Enthesitis Index\/Spondyloarthritis Research Consortium of Canada enthesitis scores and tender joint counts were significantly higher in group 4 vs group 2. PASDAS components generally improved to month 6 in all groups, consistent with modelled trajectories. There were no clear trends in AEs across groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In patients with PsA receiving tofacitinib, five distinct trajectory groups were identified with different baseline characteristics and treatment outcomes, but no clear trends in AEs. The tofacitinib 5 and 10\u2009mg twice daily models showed comparable trajectories and baseline characteristics. In patients with HDA, enthesitis and tender joint count may impact timing and\/or magnitude of response to tofacitinib. Identifying characteristics that impact treatment response may aid personalised treatment algorithm development.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration numbers<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01877668\">NCT01877668<\/jats:ext-link>\/<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01882439\">NCT01882439<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-005250","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T05:18:47Z","timestamp":1749014327000},"page":"e005250","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct01877668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01882439","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01877668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01882439","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna","family":"Gladman","sequence":"first","affiliation":[{"name":"Department of Medicine, University Health Network Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-4125","authenticated-orcid":false,"given":"William","family":"Tillett","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gruben","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C","family":"Coates","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Hahne","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail","family":"Volkov","sequence":"additional","affiliation":[{"name":"Pfizer BV, Capelle aan den IJssel, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"2025090312363385000_11.2.e005250.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00293-y"},{"key":"2025090312363385000_11.2.e005250.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"2025090312363385000_11.2.e005250.3","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002559","article-title":"Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study","volume":"9","author":"Leng","year":"2023","journal-title":"RMD Open"},{"key":"2025090312363385000_11.2.e005250.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"2025090312363385000_11.2.e005250.5","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(21)00010-2","article-title":"Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study","volume":"3","author":"Nash","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025090312363385000_11.2.e005250.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"2025090312363385000_11.2.e005250.7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.clinpsy.121208.131413"},{"key":"2025090312363385000_11.2.e005250.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2025090312363385000_11.2.e005250.9","doi-asserted-by":"crossref","unstructured":"Nagin D . Group-based modeling of development. Cambridge, MA: Harvard University Press, 2005.","DOI":"10.4159\/9780674041318"},{"key":"2025090312363385000_11.2.e005250.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140172"},{"key":"2025090312363385000_11.2.e005250.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150826"},{"key":"2025090312363385000_11.2.e005250.12","doi-asserted-by":"publisher","DOI":"10.1109\/TAC.1974.1100705"},{"key":"2025090312363385000_11.2.e005250.13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1214\/aos\/1176344136","article-title":"Estimating the dimension of a model","volume":"6","author":"Schwarz","year":"1978","journal-title":"Ann Statist"},{"key":"2025090312363385000_11.2.e005250.14","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003809","article-title":"Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project","volume":"10","author":"Singla","year":"2024","journal-title":"RMD Open"},{"key":"2025090312363385000_11.2.e005250.15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/acr.24709","article-title":"Identification of distinct disease activity trajectories in methotrexate-naive patients with rheumatoid arthritis receiving tofacitinib over twenty-four months","volume":"74","author":"Bykerk","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312363385000_11.2.e005250.16","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-022-02918-3","article-title":"Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis","volume":"24","author":"Koo","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2025090312363385000_11.2.e005250.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274264","article-title":"Disease activity trajectories for early and established rheumatoid arthritis: Real-world data from a rheumatoid arthritis cohort","volume":"17","author":"Movahedi","year":"2022","journal-title":"PLoS One"},{"key":"2025090312363385000_11.2.e005250.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209785"},{"key":"2025090312363385000_11.2.e005250.19","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001845","article-title":"Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis","volume":"7","author":"Pournara","year":"2021","journal-title":"RMD Open"},{"key":"2025090312363385000_11.2.e005250.20","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002934","article-title":"Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-na\u00efve population of patients with PsA","volume":"9","author":"Richette","year":"2023","journal-title":"RMD Open"},{"key":"2025090312363385000_11.2.e005250.21","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1007\/s10067-024-07193-y","article-title":"Factors predicting treatment response to biological and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review and meta-analysis","volume":"43","author":"K\u00fcnzler","year":"2024","journal-title":"Clin Rheumatol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-005250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:36:38Z","timestamp":1756928198000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-005250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,3]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/rmdopen-2024-005250"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-005250","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}